






PHARMACEUTICAL 2020

Rein Therapeutics Inc Rank 247 of 363

The relative strengths and weaknesses of Rein Therapeutics Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Rein Therapeutics Inc compared to the market average is the variable Other Assets, increasing the Economic Capital Ratio by 30% points. The greatest weakness of Rein Therapeutics Inc is the variable Comprehensive Net Income, reducing the Economic Capital Ratio by 66% points.

The company's Economic Capital Ratio, given in the ranking table, is 170%, being 68% points below the market average of 238%.

Input Variable	Value in 1000 USD
Assets, Current	19,550
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	5,839
Liabilities, Non-Current	4,586
Other Assets	6,628
Other Compr. Net Income	12
Other Expenses	0
Other Liabilities	0
Other Net Income	587
Other Revenues	0
Property and Equipment	295
Research and Development	17,663
Selling, General and Administrative Expense	12,293

Output Variable	Value in 1000 USD
Assets	26,473
Liabilities	10,425
Expenses	29,956
Revenues	0
Stockholders Equity	16,048
Net Income	-29,369
Comprehensive Net Income	-29,363
BaseVar	33,726
ECR before LimitedLiability	30%
Economic Capital Ratio	170%